Yuyan Chen

List of Publications by Year
in descending order

25 papers	1,832 citations	777949 13 h-index	799663 21 g-index
26 all docs	26 docs citations	26 times ranked	3717 citing authors

#	Article	IF	Citations
1	Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer. Genes Chromosomes and Cancer, 2022, 61, 81-93.	1.5	2
2	Delayed recruiting of TPD52 to lipid droplets â€“ evidence for a â€œsecond waveâ€•of lipid droplet-associated proteins that respond to altered lipid storage induced by Brefeldin A treatment. Scientific Reports, 2019, 9, 9790.	1.6	5
3	Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer: a review of the literature. Journal of Medical Genetics, 2018, 55, 785-793.	1.5	17
4	Tumor Protein D52 (TPD52). , 2018, , 5779-5786.		0
5	Dropping in on the lipid droplet- tumor protein D52 (TPD52) as a new regulator and resident protein. Adipocyte, 2016, 5, 326-332.	1.3	5
6	Tumor Protein D52 (TPD52). , 2016, , 1-8.		0
7	TPD52 expression increases neutral lipid storage within cultured cells. Journal of Cell Science, 2015, 128, 3223-38.	1.2	31
8	Genomeâ€•wide approach to identify second gene targets for malignant rhabdoid tumors using highâ€•density oligonucleotide microarrays. Cancer Science, 2014, 105, 258-264.	1.7	12
9	TPD52 represents a survival factor in ERBB2â€•amplified breast cancer cells. Molecular Carcinogenesis, 2014, 53, 807-819.	1.3	31
10	Tumor protein D52 (TPD52) and cancerâ€”oncogene understudy or understudied oncogene?. Tumor Biology, 2014, 35, 7369-7382.	0.8	51
11	Identification of PLP2 and RAB5C as novel TPD52 binding partners through yeast two-hybrid screening. Molecular Biology Reports, 2014, 41, 4565-4572.	1.0	11
12	Tumor protein D52 represents a negative regulator of ATM protein levels. Cell Cycle, 2013, 12, 3083-3097.	1.3	26
13	Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. Oncogene, 2012, 31, 4667-4676.	2.6	49
14	Challenges in Identifying Candidate Amplification Targets in Human Cancers: Chromosome 8q21 as a Case Study. Genes and Cancer, 2012, 3, 87-101.	0.6	9
15	Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma. Cancer Science, 2011, 102, 1645-1650.	1.7	37
16	Hepatoblastoma in a Patient with Sotos Syndrome. Journal of Pediatrics, 2009, 155, 937-939.	0.9	23
17	Frequent inactivation of A20 in B-cell lymphomas. Nature, 2009, 459, 712-716.	13.7	520
18	Aberrations of Genes Regulating NF Kappa B Pathway in B-Cell Malignant Lymphoma.. Blood, 2009, 114, 971-971.	0.6	0

#	Article	IF	Citations
19	Oncogenic mutations of ALK kinase in neuroblastoma. Nature, 2008, 455, 971-974.	13.7	795
20	Genome-Wide Analysis of B Cell Non-Hodgkinâ€™s Lymphoma Disclosed Frequent Involvement of Genes in NFkB Pathway. Blood, 2008, 112, 807-807.	0.6	3
21	AML1 Mutation and FLT3-internal Tandem Duplication in Leukemia Transformed From Myelodysplastic Syndrome. Journal of Pediatric Hematology/Oncology, 2007, 29, 666-667.	0.3	1
22	Mutation and expression analyses of theMET andCDKN2A genes in rhabdomyosarcoma with emphasis onMET overexpression. Genes Chromosomes and Cancer, 2007, 46, 348-358.	1.5	38
23	High-Resolution Analyses of Genetic and Epigenetic Aberrations in Infant Leukemia with MLL Rearrangement.. Blood, 2007, 110, 4238-4238.	0.6	0
24	Mutations of thePTPN11 andRAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes and Cancer, 2006, 45, 583-591.	1.5	70
25	Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene, 2001, 20, 4424-4432.	2.6	92